A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis

Drugs for Neglected Diseases

Status and phase: Active, not recruiting; Phase 2

Conditions: Primary Visceral Leishmaniasis

Treatments: Other: Placebo; Drug: AmBisome®; Drug: LXE408

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05593666

CLXE408A12201R (Other Identifier)

DNDi-LXE408-01-VL

Details and patient eligibility

About

This is a phase II, multicentre, randomized, two-arm blinded study with an open label calibrator arm in adults and adolescents (≥12 years) with confirmed primary VL.

Full description

This study is run by DNDi with Novartis as co-development partner

Enrollment: 101 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female patients ≥ 18 years (at the time of the screening visit) who are able to comply with the study protocol. Following a favourable interim analysis result, patients ≥12 <18 years will also be enrolled in the trial
• Patients for whom written informed consent has been obtained (if aged 18 years and over) or signed by parent(s) or legal guardian for patients under 18 years of age. In the case of minors, assent from the child also needs to be obtained
• Primary symptomatic VL (defined as typical parameters including, but not limited to, fever for > 2 weeks, weight loss, and splenomegaly)
• Visualization of Leishmania amastigotes by microscopy in tissue samples (spleen or bone marrow)

Exclusion criteria

• Clinical signs of severe VL (jaundice, spontaneous bleeding, edema, ascites, coma, organ failure)
• Laboratory abnormalities including ALT/SGPT > 3 times ULN, total bilirubin > 1.5 times ULN, creatinine >1.5 times ULN, amylase or lipase > 1.5 times ULN, haemoglobin < 6 g/dL or other clinically significant abnormal laboratory parameters which, in the opinion of the investigator, may indicate severe VL
• Patients with history of previous leishmaniasis and confirmed relapse
• Patients with para-kala-azar dermal leishmaniasis
• Patients with severe malnutrition (for children ≥12-<18 years: BMI-for-age WHO reference curves by sex, z score < -3; for adults ≥18 years: BMI < 16)
• History of congenital or acquired immunodeficiency, including positive HIV (test at screening)
• Known hypersensitivity to amphotericin B deoxycholate or any other constituents of AmBisome®
• Concomitant infections such as tuberculosis, severe malaria, or any other serious underlying disease that may interfere with the disease assessment (e.g., cardiac, renal, hepatic, haematologic, and pancreatic)
• Infection with hepatitis B (HBV) or hepatitis C virus (HCV). A positive HBV surface antigen (HBsAg) test, or if standard local practice, a positive HBV core antigen test, excludes a subject. Patients with a positive HCV antibody test should have HCV RNA levels measured. Patients with positive (detectable) HCV RNA should be excluded.
• Pregnant or nursing (lactating) women
• Women of childbearing potential who do not accept to have a pregnancy test done at screening and/or who do not agree to use highly effective contraception while taking the investigational drug and for 5 half-lives or 5 days, whichever is longer, after stopping the investigational drug.
• Sexually active males unwilling to use a condom during intercourse while taking the investigational drug and for 5 half-lives or 5 days, whichever is longer, after stopping the investigational drug.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

101 participants in 3 patient groups

LXE408 short regimen

Experimental group

Description:

LXE408 once daily for seven days (followed by 7 days of placebo).

Treatment:

Drug: LXE408

Other: Placebo

LXE408 long regimen

Experimental group

Description:

LXE408 once daily for 14 days

Treatment:

Drug: LXE408

Standard of care

Active Comparator group

Description:

AmBisome® 10 mg/kg IV single dose (SDA)

Treatment:

Drug: AmBisome®